What's new in research

Le diabète, la recherche et l'accompagnement.

Diabetes, Research and Support

What's New in research?

The research

In this tab, I wanted to deepen the topic, because usually have little read on the websites everything related diabetes, but very little on medical research. I also wanted to see and compare what is happening in Canada, Quebec and France. I managed through my research to find you a great team of employees.

 

I introduce you,

 

 

 

 

Réseau de recherche en santé CardioMétabolique, Diabète et Obésité (CMDO) du FRQS

 

Faculty of Medicine and Health Sciences

University of Sherbrooke

CRCHUS

 

  • For France this remains to be confirmed.

 

DIABETES AND CHRONIC PAIN: RESEARCHERS WILL SHERBROOKE CANADA-WIDE NETWORK PART

Posted by Marie-France Martel (Estrie) 107.7 Estrie Friday, April 8, 2016 at 14:30. Edited by Vincent Franche-Lombart at 4:52 p.m..

 

Two research teams at the CHUS are now part of the new Canadian patient-oriented research strategy.

 

An amount of $ 50 million over 5 years was allocated for research on diabetes and chronic pain, and 3 million will be dedicated to research done in Sherbrooke.

 

Regarding chronic pain, researchers will be involved in the study medication.

 

In terms of diabetes, the Sherbrooke team will also work with researchers in Canada and internationally.

 

The CHUS team will contribute to the development of a national diabetes registry and installing a 3rd imaging device.

 

SiteLock

PRESS RELEASE

 

The artificial pancreas CHU Montpellier: towards a sustainable treatment of type 1 diabetes in everyday life.

Since the first trials in Clinical Investigation Center INSERM / University Hospital of Montpellier in 2001, the artificial pancreas has taken steps successively. It rests on a combination of continuous glucose measurement device, an insulin pump and a control software (algorithm) automated diabetes which calculates the flow of the insulin pump to maintain blood sugar in the standard. By 2 years, the artificial pancreas could be an effective treatment for type 1 diabetes.

 

Artificial pancreas: the beginning

 

The milestone was reached in October 2011 when for the first time, contemporary way to Montpellier and Padua (Italy), two diabetic patients were able to use the artificial pancreas outside the hospital (outpatient). Indeed, thanks to the collaboration of the two European academic centers with the University of Virginia in Charlottesville United States, their diabetes could be treated automatically by operation of the control software on a smartphone.

 

Since then, with the support of European research funding (project Artificial Pancreas At Home in the European Community) and American (Artificial Pancreas Initiative JDRF foundation), this initial test was extended to a larger number of patients and increasing duration.

Successive tests have confirmed the considerable reduction in the risk of nocturnal hypoglycaemia and improved time with normal blood sugar levels every day to a continuous period of two months. The patients in these trials have confirmed how all this automation control their blood sugar lightened the burden of the disease and allowed them to find safety, freedom of life and a certain insouciance.

The advanced artificial pancreas

Today, two important steps are to work. The first, supported by the Programme Hospitalier National Fundraising Clinic, extends the experience of the artificial pancreas outside the hospital in prepubertal diabetic children aged 8 to 11 already recruited Montpellier, Paris (Hôpital Robert Debré ) Tours and Angers.

 

The goal is to evaluate a few days the ability to reduce nocturnal hypoglycemia and improve diabetes control. The study is ongoing and first results confirm the achievement of objectives.

The second, funded by the US National Institute for Health (NIH), will test in real life over 6 months treatment of diabetes with an artificial pancreas using inControl® control system made ​​available by the start-up Type Zero Technologies (Charlottesville, VA, USA) in more than 200 type 1 diabetic patients recruited in seven US university centers (university of Virginia, Harvard, Mount Sinai, Mayo Clinic, Denver, Stanford, Santa Barbara) and three European academic centers (Montpellier, Padua, Amsterdam).

The objectives are to establish the safety and efficacy of the control of prolonged diabetes, opening the door to a provisioning marketed artificial pancreas.

In addition to the automated management of the administration of insulin, the device includes access to a server that allows patients to transmit and archive data and investigative teams to monitor the functioning of the system and give advice to patients in case of emergency. This study pivot to take place in 2016-2018.

Artificial pancreas: the near future

The expertise of the team of Endocrinology-Diabetes Montpellier University Hospital is also involved in the clinical development of Diabeloop® artificial pancreas project conducted in France by the CERITD and CEA-Leti. Buoyed by his knowledge and his foundational experience, as well as the constant support and enthusiasm of diabetic patients, the team of Endocrinology-Diabetes Montpellier University Hospital and contribute to the artificial pancreas goes from dream to reality in the very near future for all patients who waited this realization for many years.

The expertise of the team of Endocrinology-Diabetes Montpellier University Hospital is also involved in the clinical development of Diabeloop® artificial pancreas project conducted in France by the CERITD and CEA-Leti. Buoyed by his knowledge and his foundational experience, as well as the constant support and enthusiasm of diabetic patients, the team of Endocrinology-Diabetes Montpellier University Hospital and contribute to the artificial pancreas goes from dream to reality in the very near future for all patients who waited this realization for many years.

Note that for the moment this expertise is still under research and can not be proposed as a treatment. Moreover, the Montpellier University Hospital not looking for volunteers.

 

Pr Eric Renard, Coordinator of the Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital, and Institute of Functional Genomics, UMR CNRS 5203 / INSERM U1191 / University of Montpellier can be available to answer questions on the subject.

____________________________________________________________________________________________________________________

Press Contact

 

CHU Montpellier

 

Louise POTREL ( l-potrel@chu-montpellier.fr ) - Press

 

Such. : 04 67 33 91 83 - 06 71 60 72 62 - www.chu-montpellier.fr

PRESS RELEASE

 

The artificial pancreas CHU Montpellier: towards a sustainable treatment of type 1 diabetes in everyday life.

 

Since the first trials in Clinical Investigation Center INSERM / University Hospital of Montpellier in 2001, the artificial pancreas has taken steps successively. It rests on a combination of continuous glucose measurement device, an insulin pump and a control software (algorithm) automated diabetes which calculates the flow of the insulin pump to maintain blood sugar in the standard. By 2 years, the artificial pancreas could be an effective treatment for type 1 diabetes.

 

Artificial pancreas: the beginning

 

The milestone was reached in October 2011 when for the first time, contemporary way to Montpellier and Padua (Italy), two diabetic patients were able to use the artificial pancreas outside the hospital (outpatient). Indeed, thanks to the collaboration of the two European academic centers with the University of Virginia in Charlottesville United States, their diabetes could be treated automatically by operation of the control software on a smartphone.

 

Since then, with the support of European research funding (project Artificial Pancreas At Home in the European Community) and American (Artificial Pancreas Initiative JDRF foundation), this initial test was extended to a larger number of patients and increasing duration. Successive tests have confirmed the considerable reduction in the risk of nocturnal hypoglycaemia and improved time with normal blood sugar levels every day to a continuous period of two months. The patients in these trials have confirmed how all this automation control their blood sugar lightened the burden of the disease and allowed them to find safety, freedom of life and a certain insouciance.

 

The advanced artificial pancreas

 

Today, two important steps are to work. The first, supported by the Programme Hospitalier National Fundraising Clinic, extends the experience of the artificial pancreas outside the hospital in prepubertal diabetic children aged 8 to 11 already recruited Montpellier, Paris (Hôpital Robert Debré ) Tours and Angers. the goal is to evaluate a few days the ability to reduce nocturnal hypoglycemia and improve diabetes control. The study is ongoing and first results confirm the achievement of objectives.

 

picture 5

 

The second, funded by the US National Institute for Health (NIH), will test in real life over 6 months treatment of diabetes with an artificial pancreas using inControl® control system made ​​available by the start-up Type Zero Technologies (Charlottesville, VA, USA) in more than 200 type 1 diabetic patients recruited in seven US university centers (university of Virginia, Harvard, Mount Sinai, Mayo Clinic, Denver, Stanford, Santa Barbara) and three European academic centers (Montpellier, Padua, Amsterdam).

 

The objectives are to establish the safety and efficacy of the control of prolonged diabetes, opening the door to a provisioning marketed artificial pancreas.

 

In addition to the automated management of the administration of insulin, the device includes access to a server that allows patients to transmit and archive data and investigative teams to monitor the functioning of the system and give advice to patients in case of emergency. This study pivot to take place in 2016-2018.

 

Artificial pancreas: the near future

 

The expertise of the team of Endocrinology-Diabetes Montpellier University Hospital is also involved in the clinical development of Diabeloop® artificial pancreas project conducted in France by the CERITD and CEA-Leti. Buoyed by his knowledge and his foundational experience, as well as the constant support and enthusiasm of diabetic patients, the team of Endocrinology-Diabetes Montpellier University Hospital and contribute to the artificial pancreas goes from dream to reality in the very near future for all patients who waited this realization for many years.

 

Note that for the moment this expertise is still under research and can not be proposed as a treatment. Moreover, the Montpellier University Hospital not looking for volunteers.

 

Pr Eric Renard, Coordinator of the Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital, and Institute of Functional Genomics, UMR CNRS 5203 / INSERM U1191 / University of Montpellier can be available to answer questions on the subject.

 

__________________________________________________________________________________________________

 

Press Contact

 

CHU Montpellier

 

Louise POTREL ( l-potrel@chu-montpellier.fr ) - Press

 

Such. : 04 67 33 91 83 - 06 71 60 72 62 - www.chu-montpellier.fr

SiteLock